{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:03:49Z","timestamp":1781870629577,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116744","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:03:30Z","timestamp":1776013410000},"page":"116744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy"],"prefix":"10.1016","volume":"240","author":[{"given":"Edurne","family":"Arriola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0479-9417","authenticated-orcid":false,"given":"Ignacio","family":"Casarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlatida","family":"Maneenil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5950","authenticated-orcid":false,"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Valdiviezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0060-5365","authenticated-orcid":false,"given":"Azura","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bolanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-4835","authenticated-orcid":false,"given":"Rachel","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116744_bib1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib2","unstructured":"Data.gov. Royal College of Physicians NLCA 2018 information sheet."},{"key":"10.1016\/j.ejca.2026.116744_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ejca.2026.116744_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061738","article-title":"Real-world journey of unresectable stage III NSCLC patients: current dilemmas for disease staging and treatment","volume":"11","author":"Agbarya","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2026.116744_bib5","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3747\/co.27.6047","article-title":"Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116744_bib7","first-page":"181","article-title":"The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study","volume":"22","author":"Iyer","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2026.116744_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib10","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-25-0292","article-title":"Leveraging longitudinal patient-reported outcome trajectories to predict survival in non\u2013small cell lung cancer","volume":"31","author":"Zhou","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116744_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.ejca.2026.116744_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001570","article-title":"A systematic review of evidence on the links between patient experience and clinical safety and effectiveness","volume":"3","author":"Doyle","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2026.116744_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4143\/crt.2018.125","article-title":"EGFR mutation is associated with short progression-free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.116744_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jrr\/rrw075","article-title":"The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis","volume":"57","author":"Ochiai","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ejca.2026.116744_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib16","first-page":"e2","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2024.3","volume":"43","author":"Owen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib17","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of stage III non\u2013small cell lung cancer: ASCO Guideline Rapid Recommendation Update","volume":"42","author":"Daly","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Pisters","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116744_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib27","article-title":"Survival with osimertinib plus chemotherapy in EGFR-Mutated Advanced NSCLC","author":"Janne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib28","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116744_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","article-title":"Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","volume":"125","author":"Leighl","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116744_bib30","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1078-0432.CCR-21-3530","article-title":"Health-related quality of life outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer who received adjuvant osimertinib in the phase III ADAURA trial","volume":"28","author":"Majem","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116744_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116744_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group Qual Life","volume":"30a","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116744_bib33","unstructured":"National Cancer Institute. Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE\u00ae). 2025."},{"key":"10.1016\/j.ejca.2026.116744_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116744_bib35","unstructured":"Scott N.W., Fayers P.M., Aaronson N.K., Bottomley A. EORTC CLQ-C30. Reference values. 2008."},{"key":"10.1016\/j.ejca.2026.116744_bib36","unstructured":"\u00d6zg\u00fcro\u011flu M., Ahn M.-J., Dong X., Yang J.C.-H., Oizumi S., Goto K., et al. Osimertinib after definitive chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC: subsequent treatments and post-progression outcomes from the phase III LAURA study. 2025."},{"key":"10.1016\/j.ejca.2026.116744_bib37","unstructured":"U.S. Food and Drug Administration. FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy. 2024."},{"key":"10.1016\/j.ejca.2026.116744_bib38","article-title":"Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer","volume":"48","author":"Shi","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ejca.2026.116744_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.lungcan.2018.05.003","article-title":"Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer","volume":"122","author":"Sebastian","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116744_bib40","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.2017.77.2293","article-title":"Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non\u2013small-cell lung cancer: the AURA3 trial","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:23:48Z","timestamp":1779294228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S0959804926005253"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116744","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116744"}}